4Estlin EJ,Ronghe M,Burke GA,et al.The clinical and cellular ph-armacology of vincristine,corticosteroids,L-ASParaginase,anthrac-yclines and cyclophosphamide in relation to childhood acute lymphoblastic leukemia[J].Br J Haematol,2000,110(4):780-790.
5Howard SC,Pui CH.Endocrine complications in pediatric pat-ients with acute lymphoblastic leukemia[J].Blood Rev,2002,16(4):225-243.
6张之楠主编.血液病诊断及疗效标准[M].2版.北京:北京科学出版社,1998:190.
7Estlin EJ,Ronghe M,Burke GA,et al.The clinical and cellular pharmacology of vincristine,L-asparaginase,anthracyclines and cyclophaminde in relation to childhood acute lymphoblastic leukemia[J].BrJ Haematol,2000(110):780-90.
8Andrew M,Brooker L,Mitchell L.Acquired antithromb in deficiency secondary to asparaginase therapy in childhood acute lymphblastic leukaemia[J].Blood Coagul Fibrinol,1994(5):524-6.
9Mitchell GL,The PARKAA Group.A prospective cohort study determining the prevalence of thromboticevents in children with acute lymphoblastic leukemia and a central venous line who aretreated with D-asparaginase[J].Cancer,2003(97):508-16.
10Wlazlowski M, Celinska W, Maciejka-Kapuscinska L, et al.Acute pancreatitis in children with acute lymphoblastic leukemia treated with L-asparaginase [J]. Pol Tyg Lek, 1994,49(12-13): 296.
